A more upbeat financial results statement from Germany’s Merck KGaA (MRK: DE) reflects rebounding sales in key markets, with falling COVID-19 rates enabling countries to relax lockdown measures.
In line with analysts’ expectations, sales rose by 3.7% to 4.1 billion euros ($4.86 billion) in the second quarter, while earnings before interest, taxes, depreciation, and amortization (EBITDA) fell 5.7% to 1.1 billion euros.
Merck said its healthcare and performance materials units have been more severely affected by the COVID-19 pandemic, compared with life sciences.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze